Skip to main content

NEW YORK (TheStreet) -- Heron Therapeutics (HRTX) - Get Heron Therapeutics Inc Report shares are up 8.63% to $28.33 in morning trading on Wednesday after the company announced the pricing of its secondary public offering of 4.8 million shares at $24.75 per share.

The gross profit from the offering is expected to be approximately $119 million with proceeds to facilitate the launch of its extended release granisetron injection SUSTOL.

The offering is expected to close June 15 with Jefferies (JEF) - Get Jefferies Financial Group Inc. Report, Leerink Partners and Cowen (COWN) - Get Cowen Inc Class A Report acting as joint book-runners for the offering.

Shares are trading at five times their normal daily volume so far today.

TheStreet Recommends

Image placeholder title

HRTX

data by

YCharts